Results 181 to 190 of about 23,497 (215)

Virtual screening, molecular docking studies and DFT calculations of FDA approved compounds similar to the non-nucleoside reverse transcriptase inhibitor (NNRTI) efavirenz

Heliyon, 2020
Maryam A Jordaan, Oluwakemi Ebenezer, Nkululeko E Damoyi   +2 more
exaly  

Identification of “dual-site”-binding diarylpyrimidines targeting both NNIBP and the NNRTI adjacent site of the HIV-1 reverse transcriptase

European Journal of Medicinal Chemistry, 2023
Da Feng, Hao Lin, Christophe Pannecouque
exaly  

NNRTIs: challenges and opportunities

Inpharma Weekly, 2002
openaire   +1 more source

Discovery, synthesis, and optimization of an N-alkoxy indolylacetamide against HIV-1 carrying NNRTI-resistant mutations from the Isatis indigotica root

European Journal of Medicinal Chemistry, 2020
Ying Guo, Jian-Gong Shi
exaly  

EMEA approves new NNRTI

Inpharma Weekly, 2008
openaire   +1 more source

Switching to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of non-nucleoside reverse transcriptase inhibitor with emtricitabine and tenofovir in virologically suppressed adults with HIV (STRATEGY-NNRTI): 48 week results of a randomised, open-label, phase 3b non-inferiority trial

Lancet Infectious Diseases, The, 2014
Anton L Pozniak, Pere Domingo
exaly  

Structural optimization of pyridine-type DAPY derivatives to exploit the tolerant regions of the NNRTI binding pocket

European Journal of Medicinal Chemistry, 2016
Peng Zhan, Dirk Daelemans, Boshi Huang
exaly  

New NNRTIs Target Resistant HIV

Internal Medicine News, 2006
openaire   +1 more source

Cost-effectiveness of public-health policy options in the presence of pretreatment NNRTI drug resistance in sub-Saharan Africa: a modelling study

Lancet HIV,the, 2018
Andrew N Phillips, Valentina Cambiano, Paul Revill   +2 more
exaly  

Activity and molecular modeling of a new small molecule active against NNRTI-resistant HIV-1 mutants

European Journal of Medicinal Chemistry, 2009
Antonio Carta, Sabrina Pricl, Sandra Piras   +2 more
exaly